Iliac, Common and External (ICE) Artery Stent Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

660 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this prospective, randomized,controlled and multicenter trial is, to compare recurrent-restenosis rates in the balloon expandable VISIO-PRO stent arm and the selfexpandable PROTEGE GPS stent arm 12 month after treatment of stenosis or occlusions of common and external iliac artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis

NCT01398033

In-stent Stenosis of Infrapopliteal Arteries

WITHDRAWN PHASE3

The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.

NCT00289055

Arterial Occlusive Diseases

TERMINATED PHASE4

Evaluation of Luminal Expansion Following Stenting of Femoro-popliteal Occlusive Disease

NCT01643746

Femoropopliteal Stenosis

WITHDRAWN NA

Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery

NCT01083394

Peripheral Vascular Disease

UNKNOWN PHASE4

LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis

NCT00930813

Atherosclerosis Vascular Disease Arteriosclerosis

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Lesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Balloon expandable stent arm

First placement of the sheath and successful passage of a 0.018" or 0.035" guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted

Group Type ACTIVE_COMPARATOR

PROTEGE GPS stent vs. VISI-PRO stent

Intervention Type DEVICE

Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease

Selfexpanding stent arm

First placement of the sheath and successful passage of a 0.018" or 0.035" guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter.

Group Type ACTIVE_COMPARATOR

PROTEGE GPS stent vs. VISI-PRO stent

Intervention Type DEVICE

Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PROTEGE GPS stent vs. VISI-PRO stent

Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ev3 peripheral stents iliac artery PAOD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 21 years.
2. Patient must sign informed consent form.
3. Patient must agree to participate in the study and comply with follow-up requirements.
4. Clinically, all patients must be in Rutherford category 1 to 4.

5. Planned stenting (degree of stenosis 70-100%) within the common or external iliac artery. The target lesion must not extend beyond the iliac arteries.
6. Lesion segment starts at the aortic bifurcation and ends at the take off of the common femoral artery (Offset of the iliac circumflex artery beneath the ligamentum inguinale).
7. The length of the lesion should be at least 1 cm and maximally 20 cm (measurement by radiopaque ruler).
8. The degree of target lesion stenosis must be determined by pre-interventional duplex ultrasound or (MR-) angiography.
9. Patency of ipsilateral profunda artery. Ipsi- or contralateral artery lesions of the leg can be treated prior to the treatment of the study lesion.
10. In cases of two or more stenotic regions within the segment, these are considered separate lesions if there is a nonstenotic or only mildly stenotic (\< 30%) segment of at least 2 cm in length between them. Otherwise, they are considered as single lesion. In case of separate lesions, only the proximal lesion will be taken as the target lesion!
11. A tandem lesion that can be treated with one stent will be considered as one lesion.

Exclusion Criteria

1. Patient is currently participating in another clinical trial
2. Pregnancy or pregnancy planned during study duration
3. Life expectancy less than 2 years
4. Co-morbidities preventing study participation
5. Severe coagulation disorders
6. Current treatment with anticoagulants other than aspirin, ticlopidine, clopidogrel or prasugrel.
7. Active gastric ulcer or gastrointestinal bleeding
8. Thrombotic occlusion of the target vessel within previous 4 weeks.
9. Treatment of target lesion with laser or atherectomy devices.
10. Dialysis dependency.
11. Manifest hyperthyreosis.
12. Known allergy against contrast agent that cannot be adequately controlled by usual premedication.
13. Known heparin intolerance.
14. Known paclitaxel intolerance.

Angiographic:
15. Target lesion extends into the femoral artery.
16. Symptomatic untreated inflow lesion \> 70% in ipsilateral iliac arteries. Pretreatment of iliac stenosis is possible.
17. Target Lesion is in aortic bifurcation and needs treatment with "kissing balloon technique"
18. Lesion in abdominal aorta that needs treatment.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No